AstraZeneca announced positive results from the landmark phase III DAPA─HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically─significant and clinically─meaningful reduction
AstraZeneca announced positive results from the landmark phase III DAPA─HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically─significant and clinically─meaningful reduction
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
